VAM
AGRX

Visium Asset Management’s Agile Therapeutics AGRX Stock Holding History

Visium Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-54
Closed -$943K – 1270
2014
Q2 		$943K Buy
+54
New +$781K 0.01% 545

Other funds holding AGRX

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Visium Asset Management's AGRX Position: Q3 2014 in Review

Visium Asset Management sold out of Agile Therapeutics (AGRX) in Q3 2014, closing a stake of 54 shares — an estimated $943K sold.

Visium Asset Management first reported a position in AGRX in Q2 2014 and held it in 1 quarter. The position peaked at $943K in Q2 2014. 19 funds tracked by Wall St. Rank hold AGRX as of Q3 2014.

  • Visium Asset Management reported no remaining Agile Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Visium Asset Management sold 54 Agile Therapeutics shares in Q3 2014, an estimated $943K.
  • Visium Asset Management first reported a position in Agile Therapeutics in Q2 2014 and held it in 1 quarter.
  • Visium Asset Management's Agile Therapeutics position peaked at $943K in Q2 2014.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2014.

Based on Visium Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.